NASDAQ: SLNO
Soleno Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$2.76B
52w High
$90.32
52w Low
$29.43
P/E
29.29
Volume
4.97M
Outstanding Shares
52.12M
Performance
Return analysis
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 29.86% over the last year. Free cash flow grew 217.95% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 30.8%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses.
Valuation
Stock splits
Every 15 shares became 1
Every 5 shares became 1
Profitability & growth
Analyst consensus
8
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 5, 2026
Q3 FY26 · EPS est $0.91 · Revenue est $111.76M
View